Processa Pharmaceuticals, Inc. · NASDAQ:PCSA

Processa Pharmaceuticals — Investor Presentation (November 2026)

21 slides from Processa Pharmaceuticals's investor presentation, November 2026

  1. Slide 1: Company Overview

    Company Overview November 2026 Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.

  2. Slide 2: Disclaimers

    Disclaimers The information in this Presentation has been prepared by Processa Pharmaceuticals, Inc. ("Processa"), including its subsidiary Vidya Therapeutics, Inc. ("Vidya" and, together with Processa and each of Processa's subsidiaries, the "Company") and contains information pertaining to the bus

  3. Slide 3: Processa acquired Vidya in a sign-and-close reverse merger

    Processa acquired Vidya in a sign-and-close reverse merger, establishing a foundation for current I&I strategy, anchored by VT7208 • Definitive merger agreement for a stock-for-stock transaction • Vidya’s outstanding equity interests exchanged for a combination of shares of Processa common OVERVIEW

  4. Slide 4: Advancing differentiated therapeutic programs for immunological and inflammatory disease

    Advancing differentiated therapeutic programs for immunological and inflammatory disease POTENTIAL PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 INDICATIONS Food Allergy VT7208 Chronic (BTK inhibitor) Spontaneous Once Daily Oral urticaria (CSU) Small Molecule Relapsing Multiple Sclerosis (RMS) FcRn An

  5. Slide 5: A potentially best-in-class, oral, once-daily BTK inhibitor

    VT7208 A potentially best-in-class, oral, once-daily BTK inhibitor

  6. Slide 6: VT7208 is expected to provide multiple value creation paths

    VT7208 is expected to provide multiple value creation paths CLINICALLY VALIDATED INDICATION EXPANSION CLEAR UNMET NEED / MECHANISM POTENTIAL LARGE ADDRESSABLE MARKETS • BTK inhibition established across Parallel development in food allergy, CSU: >1.7M U.S. patients1 autoimmune diseases CSU, and rela

  7. Slide 7: BTK is a compelling target

    BTK is a compelling target BTK offers the potential to modulate both adaptive and innate immune pathways CENTRAL IMMUNE B-CELLS (ADAPTIVE) MYELOID CELLS (INNATE) SIGNALING NODE BCR FcRn BCR signaling drives BTK’s dual role FcRn signaling drives • Proliferation • Links adaptive and innate • Myeloid c

  8. Slide 8: VT7208 demonstrates strong and differentiated preclinical profile

    VT7208 demonstrates strong and differentiated preclinical profile supports continued advancement into Phase 2 Strong CNS • Potent in vitro and in vivo with strong peripheral and Penetration CNS target engagement • Consistent preclinical efficacy observed across disease models • Clean metabolic profi

  9. Slide 9: VT7208 Phase 1 study design enables efficient dose escalation

    VT7208 Phase 1 study design enables efficient dose escalation and translational readouts; currently advancing into Phase 2 PoC Single Ascending Dose (SAD) Multiple Ascending Dose (MAD) Food effect crossover 60 mg 20 mg QD Escalate × 7 days Go to MAD SRC Safety SRC 20 mg 10 mg QD 20 mg SD Single dose

  10. Slide 10: VT7208 Phase 1 study results demonstrated favorable safety and tolerability

    VT7208 Phase 1 Study results demonstrated favorable safety profile and tolerability profile PARAMETER SAD FOOD EFFECT MAD (QDX7) 5 mg 20 mg 60 mg 20 mg 10 mg 20 mg SAEs 0/6 0/6 0/6 0/8 0/6 0/6 Grade 3 or higher 0/6 0/6 0/6 0/8 0/6 0/8 1/6 1/8 Related AEs 0/6 0/6 0/6 0/6 Headache (G1) Headache (G1) C

  11. Slide 11: VT7208 shows predictable PK supports low, once-daily oral dosing

    VT7208 shows predictable PK supports low, once-daily oral dosing SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE ● 5 mg ● 10 mg ● 20 mg ● 60 mg ● 10 mg ● 20 mg ━ SS ╍ CSF 1,000 1,000 100 VT7208 Conc (ng/mL) VT7208 Conc (ng/mL) 100 10 10 1 CSF 1 IC₅₀, human iPSC-derived microglia 0.1 0.1 0.01 0 12 24 3

  12. Slide 12: VT7208 demonstrated robust and sustained BTK target occupancy

    VT7208 demonstrated robust and sustained BTK target occupancy at ≥ 5 mg/day SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE ▲ Placebo ▲ 5 mg ▲ 20 mg ▲ 60 mg ▼ Placebo ▼ 10 mg ▼ 20 mg 100 100 95% 95% Peripheral Target Occupancy (%) Peripheral Target Occupancy (%) 80 75 60 40 50 20 25 0 -20 0 0 12 24 36

  13. Slide 13: VT7208 demonstrated robust and sustained inhibition of pBTK

    VT7208 demonstrated robust and sustained inhibition of pBTK demonstrated modulation of signaling pathway MULTIPLE ASCENDING DOSE ■ Placebo ■ 10 mg □ 20 mg 100 last dose 75 pBTK Inhibition (%) 50 25 0 -25 -50 0 48 96 144 192 240 288 336 Time (hrs) • Sustained inhibition of pBTK demonstrates the poten

  14. Slide 14: VT7208 Phase 1 complete; now advancing into Phase 2 PoC studies

    VT7208 Phase 1 study complete; now advancing into Phase 2 PoC studies in Food Allergy, CSU, & Relapsing MS TARGET / ASSET PRECLINICAL TRANSLATIONAL CLINICAL STRATEGIC ü Validated biology ü Potential for low risk ü Predictable PK ü Well-defined PoC ü Capital-efficient of hepatotoxicity supporting onc

  15. Slide 15: Oral FcRn antagonist

    Oral FcRn antagonist Potentially best-in-class, preclinical oral neonatal Fc receptor (FcRn) antagonist

  16. Slide 16: Oral FcRn antagonist program complements VT7208 against a clinically validated immune target

    Oral FcRn antagonist program complements VT7208 against a clinically validated immune target ANNOUNCED OCTOBER 2026 1 2 3 4 Partnership Modality Differentiation Program progression Research collaboration Macrocyclic peptide against Potential oral alternative Lead optimization through and exclusive o

  17. Slide 17: Blocking FcRn clears the pathogenic IgG that drives autoimmune disease

    Blocking FcRn clears the pathogenic IgG that drives autoimmune disease FcRn binds IgG inside cells and recycles it back to the blood, sparing it from lysosomal degradation. This gives IgG its long half-life of ~3 weeks. Blocking FcRn sends IgG, including disease-causing autoantibodies, to the lysoso

  18. Slide 18: FcRn is a commercially validated, rapidly growing therapeutic class

    FcRn is a commercially validated, rapidly growing therapeutic class $4.15B Approved FcRn Therapies $4.15B $2.2B VYVGART argenx RYSTIGGO UCB IMAAVY JnJ VYVGART 2025 global net sales A validated pathway with established prescriber infrastructure +90% vs. 2024 2024 2025 and proven commercial demand Str

  19. Slide 19: No oral FcRn therapeutic is currently in clinical development

    No oral FcRn therapeutic is currently in clinical development PROGRAM MODALITY STAGE Generian / Vidya Macrocycle Preclinical Argenx + Unnatural Products Macrocycle Preclinical Peptide Preclinical Covant Small molecule Early discovery Curie Small molecule Preclinical Fudan Small molecule Early discov

  20. Slide 20: Expected capitalization post Series A conversion

    Expected capitalization post Series A conversion Expected capitalization Approximate shares Common shares outstanding (Nov 9, 2026) 2.8 million Series A preferred, as-converted* 306.6 million Total 309.4 million * Subject to stockholder approval and applicable beneficial ownership limitations. Exclu

  21. Slide 21: Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.

    Vidya Therapeutics is a subsidiary of Process Pharmaceuticals, Inc.

Processa Pharmaceuticals — Investor Presentation (November 2026) on 6ix